Umoja Biopharma | $100,000,000 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
r4 | $1,000,000 | (Jan 21, 2025)
Certified by Founder
Lodge
Judo Bio
start up
United States
- Cambridge, MA
- 08/10/2024
- Seed
- $100,000,000
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.
- Industry Biotechnology Research
- Website https://judo.bio/
- LinkedIn https://www.linkedin.com/company/judobio/
IntusCare | $11,500,000 | (Jan 21, 2025)
Alteva Technologies | $1,760,526 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
StepChange.work | $4,000,000 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)
Pipe17 | $15,500,000 | (Jan 17, 2025)
Coram AI | $13,800,000 | (Jan 17, 2025)
Quantifind | $22,000,000 | (Jan 17, 2025)